Related references
Note: Only part of the references are listed.Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study
E. Mahe et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Body weight increment in patients treated with infliximab for plaque psoriasis
V. Florin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months
Inga-Lill Engvall et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Potential New Insight Into the Pathogenesis of Psoriasis
David T. Woodley et al.
ARCHIVES OF DERMATOLOGY (2009)
Association of Psoriasis With Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and Mortality
Srjdan Prodanovich et al.
ARCHIVES OF DERMATOLOGY (2009)
Psoriasis and the Risk of Diabetes and Hypertension
Abrar A. Qureshi et al.
ARCHIVES OF DERMATOLOGY (2009)
Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease
Ioannis E. Koutroubakis et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Effects of Infliximab Therapy on Abdominal Fat and Metabolic Profile in Patients with Crohn's Disease
Erika Parmentier-Decrucq et al.
INFLAMMATORY BOWEL DISEASES (2009)
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Vincent E. Friedewald et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody
Keiko Nishida et al.
ENDOCRINE JOURNAL (2008)
Anti-tumour necrosis factor-α therapy increases body weight in patients with chronic plaque psoriasis:: a retrospective cohort study
P. Gisondi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2008)
Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis
Rosita Saraceno et al.
PHARMACOLOGICAL RESEARCH (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Incidence and risk factors for psoriasis in the general population
Consuelo Huerta et al.
ARCHIVES OF DERMATOLOGY (2007)
The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis
F. M. Oguz et al.
ACTA CLINICA BELGICA (2007)
Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis
F. Del Porto et al.
RHEUMATOLOGY (2007)
Psoriasis: a possible risk factor for development of coronary artery calcification
R. J. Ludwig et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Improved insulin sensitivity by anti-TNF alpha antibody treatment in patients with rheumatic diseases
Frank C. Huvers et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Weight gain with tumour necrosis factor-α inhibitors
L Stamp et al.
INTERNAL MEDICINE JOURNAL (2005)
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-α antibody infliximab
B Yazdani-Biuki et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Cachexia in rheumatoid arthritis
J Walsmith et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2002)
Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy
S Iyer et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)